SMS at the peak pollen season
In ILIT after SCIT- 10 000, the median MS in the active group was
reduced with 26% at the peak pollen season after treatment compared to
before treatment. The placebo group did not improve. There was no change
in SS or CSMS within any of the groups and no difference between the
active (n=13) or placebo group (n=11) in the SS (p=0.19), MS (p=0.97) or
CSMS (p=0.58).
In ILIT de novo- 3000, the placebo group reduced the CSMS and the MS
after treatment, while the active group did not improve. There was no
difference between the active (n=15) and placebo group (n=18) after
treatment in SS (p=0.92), MS (p=0.81) or CSMS (p=0.84). (See Table E2).